



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, October 18, 2023
Minutes
Approved by the board on Nov. 15, 2023

Web link to the meeting video: <https://www.youtube.com/watch?v=516QeYcToPA&feature=youtu.be>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20231018-PDAB-document-package.pdf>.

Web link to Excel spreadsheets and data information: <https://dfr.oregon.gov/pdab/Pages/data.aspx>

Call to order and roll call: Vice Chair Shelley Bailey called the meeting to order at 9:30 am and the roll was called.

Board members present: Vice Chair Shelley Bailey, , Dr. Amy Burns, Dr. Daniel Hartung, Robert Judge, John Murray. Dr. Richard Bruno joined the meeting after the roll call and minutes were approved.

Board members absent: Chair Akil Patterson

Approval of minutes: **John Murray** made a motion and **Robert Judge** provided a second to approve the minutes on [Pages 3-7](#) in the agenda packet.

MOTION to approve the minutes.

Board Vote:

Yea: Amy Burns, Daniel Hartung, Robert Judge, John Murray, Vice Chair Shelley Bailey

Nay: None

Absent: Richard Bruno, Akil Patterson

Motion passed 5-0

Program update: Executive Director Ralph Magrish announced a change in the agenda order. The affordability review would move ahead of the policy recommendation discussion. [View the executive director's report in the meeting video at minute 00:01:40.](#)

Federal court ruling on copay accumulators: Jessie O'Brien, DFR policy manager, provided an update. [View in the meeting video at minute 00:07:18.](#)

Board continuation of affordability review outlined in OAR 925-200-0010: Ralph Magrish, executive director, reviewed the criteria on [Pages 28-45](#) of the agenda packet. [View video of the board discussion at minute 00:15:45 and vote of subset of prescription drugs at minute 01:26:40.](#) Vice Chair Shelley Bailey called for a motion to select a subset of prescription drugs to move forward with the affordability review using the list of prescription drugs indicated in Table 1 below. **Amy Burns** made a motion and **John Murray** provided a second.

MOTION selection of a subset of prescription drugs to move forward with the affordability review with the list of prescription drugs shown in Table 1:

Board Vote:

Yea: Amy Burns, Daniel Hartung, Robert Judge, John Murray, Shelley Bailey

Nay: None

Absent: Richard Bruno, Akil Patterson

Motion passed 5-0.



Table 1: Board approved subset list of prescription drugs pursuant to OAR 925-200-0010.

Non-proprietary name	Proprietary name(s)
Abacavir-Dolutegravir-Lamivudine	Triumeq / Triumeq PD
Adalimumab	Humira / Humira Pediatric Crohns Start / Humira Pen / Humira Pen-CD/UC/HS Starter / Humira Pen-Pediatric UC Start / Humira Pen-Ps/UV/Adol HS Start / Humira Pen-Psor/Uveit Starter
Aflibercept	Eylea
Albuterol Sulfate	Albuterol Sulfate / Albuterol Sulfate ER / Albuterol Sulfate HFA / ProAir HFA / ProAir RespiClick / Proventil HFA / Ventolin HFA
Apixaban	Eliquis / Eliquis DVT/PE Starter Pack
Budesonide-Formoterol Fumarate Dihydrate	Budesonide-Formoterol Fumarate / Symbicort
Dulaglutide	Trulicity
Dupilumab	Dupixent
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide	Genvoya
Empagliflozin	Jardiance
Etanercept	Enbrel / Enbrel SureClick
Guselkumab	Tremfya
Immune Globulin (Human) IV or Subcutaneous	Gammagard / Gammaked / Gamunex-C
Infliximab-dyyb	Inflectra
Lisdexamfetamine Dimesylate	Vyvanse
Nivolumab	Opdivo
Ocrelizumab	Ocrevus
OnabotulinumtoxinA	Botox
Pancrelipase (Lipase-Protease-Amylase)	Creon / Pancreaze / Pertzye / Viokace / Zenpep
Pembrolizumab	Keytruda
Risankizumab-rzaa	Skyrizi / Skyrizi Pen
Rivaroxaban	Xarelto / Xarelto Starter Pack
Secukinumab	Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready
Semaglutide	Rybelsus / Ozempic
Ustekinumab	Stelara
Vedolizumab	Entyvio

Board continuation of affordability review for insulin outlined in OAR 925-200-0010: Ralph Magrish, executive director, reviewed the criteria for insulin on [Pages 36-45](#) of the agenda packet. [View the board discussion in the meeting video at minute 01:28:45](#). Board members agreed to continue the discussion at the next regular meeting on Nov. 15, 2023.

Board review of proposed policy recommendations: Cortnee Whitlock, policy analyst, reviewed the proposed policy recommendations submitted by the public shown on [Pages 9-27](#) in the agenda packet. [View the discussion in the meeting video at minute 01:55:23](#). The board will review the draft report with recommendations on Nov. 15.

Public comment: Vice Chair Shelley Bailey called on the person who signed up in advance to speak to the board. Dharia McGrew, PhRMA, provided oral and written testimony to the board. [View the oral testimony in the meeting video at minute 02:08:08](#). Genentech also provided written testimony to the board. [The written testimony is posted on the PDAB website.](#)

Adjournment: The meeting was adjourned at 11:45 a.m. by a motion from **Robert Judge**, a second by **John Murray** and all voted in favor.